A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

NCT04344158 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

648

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Interventions

DRUG: AK105 Injection
DRUG: Anlotinib Hydrochloride Capsules
DRUG: Sorafenib Tosylate Tablets

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.